Epistemic uncertainty in Bayesian predictive probabilities

References

• Aitkin, M. 2010. Statistical inference: An integrated bayesian/likelihood approach. Chapman and Hall/CRC. doi:10.1201/EBK1420093438.
   Google Scholar
• Aitkin, M., and C. Liu. 2018. Confidence, credibility and prediction. Metron 76 (2):251–268. doi:10.1007/s40300-018-0139-1.
   Web of Science ®Google Scholar
• Bauer, P., F. Bretz, V. Dragalin, F. König, and G. Wassmer. 2016. Twenty‐five years of confirmatory adaptive designs: Opportunities and pitfalls. Statistics in Medicine 35 (3):325–347. doi:10.1002/sim.6472.
   PubMed Web of Science ®Google Scholar
• Broglio, K. R., J. T. Connor, and S. M. Berry. 2014. Not too big, not too small: a goldilocks approach to sample size selection. Journal of Biopharmaceutical Statistics 24 (3):685–705. doi:10.1080/10543406.2014.888569.
   PubMed Web of Science ®Google Scholar
• Carroll, K. J. 2013. Decision making from phase ii to phase iii and the probability of success: reassured by “Assurance”? Journal of Biopharmaceutical Statistics 23 (5):1188–1200. doi:10.1080/10543406.2013.813527.
   PubMed Web of Science ®Google Scholar
• Chen, Y. H. J., D. L. DeMets, and K. K. Gordon Lan. 2004. Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 23 (7):1023–1038. doi:10.1002/sim.1688.
   PubMed Web of Science ®Google Scholar
• Chen, D. -G., (Din), S. Ho, and (Din). 2016. From statistical power to statistical assurance: It’s time for a paradigm change in clinical trial design. Communications in Statistics - Simulation and Computation. 46 (10):7957–7971. doi:10.1080/03610918.2016.1259476.
   Web of Science ®Google Scholar
• Crisp, A., S. Miller, D. Thompson, and N. Best. 2018. Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development. Pharmaceutical Statistics 17 (4):317–328. doi:10.1002/pst.1856.
   PubMed Web of Science ®Google Scholar
• Dallow, N., and P. Fina. 2011. The perils with the misuse of predictive power. Pharmaceutical Statistics 10 (4):311–317. doi:10.1002/pst.467.
   PubMed Web of Science ®Google Scholar
• Dmitrienko, A., and M. -D. Wang. 2006. Bayesian predictive approach to interim monitoring in clinical trials. Statistics in Medicine 25 (13):2178–2195. doi:10.1002/sim.2204.
   PubMed Web of Science ®Google Scholar
• Edwards, J. M., S. J. Walters, C. Kunz, and S. A. Julious (2020). A systematic review of the “promising zone” design. Trials, 21(1), 1000. doi:10.1186/s13063-020-04931-w
   Google Scholar
• Gaffney, M., and J. H. Ware. 2017. An evaluation of increasing sample size based on conditional power. Journal of Biopharmaceutical Statistics 27 (5):797–808. doi:10.1080/10543406.2017.1289943.
   PubMed Web of Science ®Google Scholar
• Gallo, P., L. Mao, and V. H. Shih. 2014. Alternative views on setting clinical trial futility criteria. Journal of Biopharmaceutical Statistics 24 (5):976–993. doi:10.1080/10543406.2014.932285.
   PubMed Web of Science ®Google Scholar
• Guo, B., and S. Liu. 2020. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. Biometrical Journal 62 (2):339–349. doi:10.1002/bimj.201900022.
   PubMed Web of Science ®Google Scholar
• Hobbs, B. P., N. Chen, and J. J. Lee. 2018. Controlled multi-arm platform design using predictive probability. Statistical Methods in Medical Research 27 (1):65–78. doi:10.1177/0962280215620696.
   PubMed Web of Science ®Google Scholar
• Huson, L. 2009. The bayesian bootstrap in a predictive power analysis. Case Studies in Business, Industry and Government Statistics 3:18–22.
   Google Scholar
• Ji, Y., P. Liu, Y. Li, and N. Bekele. 2010. A modified toxicity probability interval method for dose-finding trials. Clinical Trials 7 (6):653–663. doi:10.1177/1740774510382799.
   PubMed Web of Science ®Google Scholar
• Kaizer, A., E. Zabor, L. Nie, B. Hobbs, and J. Zhou. 2022. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of simon’s two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. PloS One 17 (8):e0272367. doi:10.1371/journal.pone.0272367.
   PubMed Web of Science ®Google Scholar
• Kou, S. C., X. S. Xie, and J. S. Liu. 2005. Bayesian analysis of single-molecule experimental data. Journal of the Royal Statistical Society: Series C (Applied Statistics) 54 (3):469–506. doi:10.1111/j.1467-9876.2005.00509.x.
   Google Scholar
• Kunzmann, K., M. J. Grayling, K. M. Lee, D. S. Robertson, K. Rufibach, and J. M. S. Wason. 2021. A review of bayesian perspectives on sample size derivation for confirmatory trials. The American Statistician 75 (4):424–432. doi:10.1080/00031305.2021.1901782.
   PubMed Web of Science ®Google Scholar
• Lan, K. K. G., P. Hu, and M. A. Proschan. 2009. A conditional power approach to the evaluation of predictive power. Statistics in Biopharmaceutical Research 1 (2):131–136. doi:10.1198/sbr.2009.0035.
   Web of Science ®Google Scholar
• Lan, K. K. G., and J. Wittes. 1988. The B-Value: A tool for monitoring data. Biometrics 44 (2):579. doi:10.2307/2531870.
   PubMed Web of Science ®Google Scholar
• Lee, J. J., and D. D. Liu. 2008. A predictive probability design for phase II cancer clinical trials. Clinical Trials 5 (2):93–106. doi:10.1177/1740774508089279.
   PubMed Web of Science ®Google Scholar
• Liu, M., and E. V. Dressler. 2018. A predictive probability interim design for phase II clinical trials with continuous endpoints. Statistics in Medicine 37 (12):1960–1972. doi:10.1002/sim.7659.
   PubMed Web of Science ®Google Scholar
• Liu, L., S. Hsiao, and C. R. Mehta. 2018. Efficiency considerations for group sequential designs with adaptive unblinded sample size re-assessment. Statistics in Biosciences 10 (2):405–419. doi:10.1007/s12561-017-9188-x.
   Web of Science ®Google Scholar
• Liu, M., S. -J. Wang, and Y. Ji. 2020. The i3+3 design for phase I clinical trials. Journal of Biopharmaceutical Statistics 30 (2):294–304. doi:10.1080/10543406.2019.1636811.
   PubMed Web of Science ®Google Scholar
• Mander, A. P., and M. J. Sweeting. 2015. A product of independent beta probabilities dose escalation design for dual‐agent phase I trials. Statistics in Medicine 34 (8):1261–1276. doi:10.1002/sim.6434.
   PubMed Web of Science ®Google Scholar
• Mehta, C. R., and S. J. Pocock. 2011. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 30 (28):3267–3284. doi:10.1002/sim.4102.
   PubMed Web of Science ®Google Scholar
• Morita, S., P. F. Thall, and P. Müller. 2008. Determining the effective sample size of a parametric prior. Biometrics 64 (2):595–602. doi:10.1111/j.1541-0420.2007.00888.x.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., A. Matano, Z. Tang, S. Roychoudhury, S. Wandel, and S. Bailey. 2014. A bayesian industry approach to phase i combination trials in oncology. In Statistical methods in drug combination studies, 95–135. Boca Raton, FL: Chapman and Hall/CRC.
   Google Scholar
• Nicolae, D. L., X. -L. Meng, and A. Kong. 2008. Quantifying the fraction of missing information for hypothesis testing in statistical and genetic studies. Statistical Science 23 (3). doi:10.1214/07-STS244.
   PubMed Web of Science ®Google Scholar
• O’Hagan, A., and J. E. Oakley. 2004. Probability is perfect, but we can’t elicit it perfectly. Reliability Engineering & System Safety 85 (1–3):239–248. doi:10.1016/j.ress.2004.03.014.
   Web of Science ®Google Scholar
• O’Hagan, A., J. W. Stevens, and M. J. Campbell. 2005. Assurance in clinical trial design. Pharmaceutical Statistics 4 (3):187–201. doi:10.1002/pst.175.
   Web of Science ®Google Scholar
• Pritchett, Y. L., S. Menon, O. Marchenko, Z. Antonijevic, E. Miller, M. Sanchez-Kam, C. C. Morgan-Bouniol, H. Nguyen, and W. R. Prucka. 2015. Sample size re-estimation designs in confirmatory clinical trials—current state, statistical considerations, and practical guidance. Statistics in Biopharmaceutical Research 7 (4):309–321. doi:10.1080/19466315.2015.1098564.
   Web of Science ®Google Scholar
• Roberts, R., C. Croft, H. K. Gold, T. D. Hartwell, A. S. Jaffe, J. E. Muller, S. M. Mullin, C. Parker, E. R. Passamani, W. K. Poole, et al. 1984. Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. The New England Journal of Medicine 311 (4):218–225. doi:10.1056/NEJM198407263110403.
   PubMed Web of Science ®Google Scholar
• Rufibach, K., H. U. Burger, and M. Abt. 2016. Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development. Pharmaceutical Statistics 15 (5):438–446. doi:10.1002/pst.1764.
   PubMed Web of Science ®Google Scholar
• Saville, B. R., J. T. Connor, G. D. Ayers, and J. Alvarez. 2014. The utility of bayesian predictive probabilities for interim monitoring of clinical trials. Clinical Trials 11 (4):485–493. doi:10.1177/1740774514531352.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., and L. S. Freedman. 1986. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Statistics in Medicine 5 (1):1–13. doi:10.1002/sim.4780050103.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., L. S. Freedman, and P. R. Blackburn. 1986. Monitoring clinical trials: Conditional or predictive power? Controlled Clinical Trials 7 (1):8–17. doi:10.1016/0197-2456(86)90003-6.
   PubMedGoogle Scholar
• Sweeting, M., A. Mander, and T. Sabin. 2013. Bcrm: Bayesian continual reassessment method designs for phase i dose-finding trials. Journal of Statistical Software 54 (13). doi:10.18637/jss.v054.i13.
   Web of Science ®Google Scholar
• Tang, Z. 2015. Optimal futility interim design: A predictive probability of success approach with time-to-event endpoint. Journal of Biopharmaceutical Statistics 25 (6):1312–1319. doi:10.1080/10543406.2014.983646.
   PubMed Web of Science ®Google Scholar
• Tang, Z. 2017. Defensive efficacy interim design: Dynamic benefit/risk ratio view using probability of success. Journal of Biopharmaceutical Statistics 27 (4):683–690. doi:10.1080/10543406.2016.1198370.
   PubMed Web of Science ®Google Scholar
• Thomas, D., D. Chancellor, A. Micklus, S. LaFever, M. Hay, S. Chaudhuri, R. Bowden, and A. W. Lo (2021). Clinical development success rates and contributing Factors 2011–2020. https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf
   Google Scholar
• Walter, S. D., H. Han, G. H. Guyatt, D. Bassler, N. Bhatnagar, V. Gloy, S. Schandelmaier, and M. Briel. 2020. A systematic survey of randomised trials that stopped early for reasons of futility. BMC Medical Research Methodology 20 (1):10. doi:10.1186/s12874-020-0899-1.
   PubMed Web of Science ®Google Scholar
• Wang, Y., H. Fu, P. Kulkarni, and C. Kaiser. 2013. Evaluating and utilizing probability of study success in clinical development. Clinical Trials 10 (3):407–413. doi:10.1177/1740774513478229.
   PubMed Web of Science ®Google Scholar
• Wang, M., G. F. Liu, and J. Schindler. 2015. Evaluation of program success for programs with multiple trials in binary outcomes. Pharmaceutical Statistics 14 (3):172–179. doi:10.1002/pst.1670.
   PubMed Web of Science ®Google Scholar
• Zhou, H., Y. Yuan, and L. Nie. 2018. Accuracy, safety, and reliability of novel phase i trial designs. Clinical Cancer Research 24 (18):4357–4364. doi:10.1158/1078-0432.CCR-18-0168.
   PubMed Web of Science ®Google Scholar
• Zierhut, M., P. Bycott, M. Gibbs, B. Smith, and P. Vicini. 2016. Ignorance is not bliss: Statistical power is not probability of trial success. Clinical Pharmacology & Therapeutics 99 (4):356–359. doi:10.1002/cpt.257.
   PubMed Web of Science ®Google Scholar